Sqz Biotechnologies CO SQZ
We take great care to ensure that the data presented and summarized in this overview for SQZ Biotechnologies Co is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in SQZ
Top Purchases
Top Sells
About SQZ
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with other immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with other immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. SQZ Biotechnologies Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.
Insider Transactions at SQZ
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 15
2022
|
Richard Capasso Officer |
SELL
Open market or private sale
|
Direct |
1,183
-100.0%
|
$3,549
$3.33 P/Share
|
|
Jun 30
2022
|
Armon Sharei President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
2,436
+0.84%
|
$4,872
$2.7 P/Share
|
|
Jun 30
2022
|
Lawrence J Knopf General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
1,484
+43.37%
|
$2,968
$2.7 P/Share
|
|
Jun 30
2022
|
Richard Capasso Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,183
+50.0%
|
$2,366
$2.7 P/Share
|
|
May 25
2022
|
Klavs F. Jensen Director |
BUY
Open market or private purchase
|
Direct |
14,326
+3.9%
|
$42,978
$3.52 P/Share
|
|
Jan 12
2022
|
Armon Sharei President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
13,000
+4.36%
|
$13,000
$1.81 P/Share
|
|
Dec 31
2021
|
Lawrence J Knopf General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
454
+50.0%
|
$3,178
$7.59 P/Share
|
|
Dec 31
2021
|
Armon Sharei President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
1,686
+0.62%
|
$11,802
$7.59 P/Share
|
|
Dec 22
2021
|
Amy W Schulman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
24,130
+3.74%
|
$72,390
$3.73 P/Share
|
|
Dec 22
2021
|
Armon Sharei President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
11,049
+3.92%
|
$11,049
$1.81 P/Share
|
|
Dec 13
2021
|
Amy W Schulman Director |
BUY
Open market or private purchase
|
Indirect |
3,700
+50.0%
|
$37,000
$10.91 P/Share
|
|
Feb 27
2021
|
Armon Sharei President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
8,000
+2.99%
|
$8,000
$1.81 P/Share
|
|
Jan 08
2021
|
Armon Sharei President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+0.98%
|
$2,500
$1.81 P/Share
|
|
Nov 03
2020
|
Temasek Holdings (Private) LTD > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
625,000
+19.91%
|
$10,000,000
$16.0 P/Share
|
|
Nov 03
2020
|
Temasek Holdings (Private) LTD > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
1,888,924
+50.0%
|
-
|
|
Nov 03
2020
|
Amy Schulman, As Trustee The Armon R. Sharei Irrevocable Gst Trust Of 2016, U/D/T Dated December 29, 2016 > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
11,025
+2.78%
|
-
|
|
Nov 03
2020
|
Polaris Management Co. Vii, L.L.C. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
250,000
+8.4%
|
$4,000,000
$16.0 P/Share
|
|
Nov 03
2020
|
Polaris Management Co. Vii, L.L.C. > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
2,477,646
+50.0%
|
-
|
|
Nov 03
2020
|
Amy W Schulman Director |
BUY
Open market or private purchase
|
Indirect |
250,000
+8.4%
|
$4,000,000
$16.0 P/Share
|
|
Nov 03
2020
|
Amy W Schulman Director |
BUY
Conversion of derivative security
|
Indirect |
2,753,506
+50.0%
|
-
|